Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods.

Nucleic acids research·2023
Same author

Illuminating the druggable genome through patent bioactivity data.

PeerJ·2023
Same author

Biomedical data analyses facilitated by open cheminformatics workflows.

Journal of cheminformatics·2023
Same author

Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics.

Nature communications·2021
Same author

Target-Based Evaluation of "Drug-Like" Properties and Ligand Efficiencies.

Journal of medicinal chemistry·2021
Same author

Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19.

Nature medicine·2021
Same journal

From mitochondrial signal to discovery decision: a reserve-demand framework for translational Risk assessment.

Expert opinion on drug discovery·2026
Same journal

Advances in 3D cell culture models for alzheimer's disease drug discovery.

Expert opinion on drug discovery·2026
Same journal

Are patient-derived models of amyotrophic lateral sclerosis a game changer for novel drug discovery?

Expert opinion on drug discovery·2026
Same journal

Unfolding prion misfolding and the challenge of identifying effective therapeutics: is there hope on the horizon?

Expert opinion on drug discovery·2026
Same journal

Balancing optimism versus potential risks of AI-driven drug discovery.

Expert opinion on drug discovery·2026
Same journal

Trustworthy and explainable AI for drug discovery.

Expert opinion on drug discovery·2026
See all related articles

Related Experiment Video

Updated: May 13, 2026

Protein Target Prediction and Validation of Small Molecule Compound
10:21

Protein Target Prediction and Validation of Small Molecule Compound

Published on: February 23, 2024

Drug target central.

Lee Harland1, Anna Gaulton

  • 1Pfizer Regenerative Medicine, Granta Park, Cambridge, UK +44 1304641575 ; Lee.Harland@pfizer.com.

Expert Opinion on Drug Discovery
|March 19, 2013
PubMed
Summary
This summary is machine-generated.

Building a comprehensive drug target database requires integrating diverse data sources and informatics approaches. This system aids drug discovery, repurposing, and understanding biological pathways.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Related Experiment Videos

Last Updated: May 13, 2026

Protein Target Prediction and Validation of Small Molecule Compound
10:21

Protein Target Prediction and Validation of Small Molecule Compound

Published on: February 23, 2024

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Area of Science:

  • Pharmacology
  • Bioinformatics
  • Drug Discovery

Background:

  • Drug targets are central to drug discovery, linking drugs to biological processes.
  • Developing informatics approaches is key to cataloging known drug targets.

Purpose of the Study:

  • To review the construction of an integrated enterprise target-informatics system using Pfizer's internal database.
  • To explore data integration from competitor intelligence, pharmacological activity, and text-mining.

Main Methods:

  • Data integration from multiple resources.
  • Application of text-mining techniques.
  • Development of structured ontologies for target representation.

Main Results:

  • Construction of an enterprise-level target-informatics system.
  • Addressing data standards and ontological complexities.
  • Identifying opportunities for future system development.

Conclusions:

  • Drug target databases support chemogenomics, drug repurposing, and business intelligence.
  • Maintaining accurate target databases is crucial for the expanding druggable genome.
  • These databases facilitate broader scientific understanding of cellular pathways.